The Medicare Part D prescription drug benefit has helped improve the affordability of medications for people with Medicare. Yet Part D enrollees can face relatively high out-of-pocket costs because the Part D benefit does not have a hard cap on out-of-…
This data note summarizes our most recent polling on the public’s experiences with and worries about health care costs, and it highlights where Americans place costs on their list of health care issues for the government to address and for political c…
This data note summarizes our most recent polling on the public’s experiences with and worries about health care costs, and it highlights where Americans place costs on their list of health care issues for the government to address and for political c…
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
As policymakers debate how to address the high cost of prescription drugs, a new KFF analysis compares data on prescription drug spending and use across large employer plans, Medicare Part D and Medicaid, and provides context for policy discussions abo…
Prescription drug costs are a pressing concern for both consumers and policymakers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which…
For the seventh year in a row, Missouri will retain its lonely title as the only state without a statewide prescription drug monitoring program. Fears about privacy violations and gun control scuttled the bill yet again, leaving a pastiche of half-step measures in place to fill the void in the fight against prescription drug abuse.
